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ABSTRACT 
 
Background: Malnutrition is highly prevalent and strongly associated with clincial outcomes of medical inpatients. 
Still, the benefit of nutritional treatment to prevent adverse outcomes in medical inpatients at risk for malnutrition 
remains unproven. We describe the trial methods of the largest yet nutritional trial in medical inpatients including the 
rationale for key design decisions regarding the nutritional strategy, eligibility criteria, choice of control arm, and 
endpoints.  
Methods: The Effect of early nutritional therapy on Frailty, Functional Outcomes and Recovery of malnourished 
medical inpatients Trial (EFFORT) is an investigator-initiated, non-commercial, open-label RCT to compare the 
effects of an intensified nutritional therapy (intervention group) with a control group on medical outcomes. We 
include adult medical inpatients at risk of malnutrition based on a Nutritional Risk Screening 2002 (NRS) score of ≥3 
points with an expected length of stay of ≥5 days. An individualized systematic nutritional assessment by study 
dieticians is done to define nutritional targets and to establish an implementation plan. Patients in the intervention 
group receive individualized early nutritional therapy based on a previously published consensus algorithm, while 
control group patients receive standard hospital nutrition. The study is powered to compare clinical outcomes 
(composite adverse outcome and mortality) in the 2 study arms as well as to address several mechanistical questions.  
Conclusion: EFFORT aims to close important gaps in the literature regarding the controversy about benefit and 
possible harm of nutritional therapy in medical inpatients at risk for malnutrition. 
Trial Registration: ClinicalTrials.gov NCT02517476; registered July 30, 2015.  
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INTRODUCTION 
Malnutrition is reported in 30-50% of medical inpatients 
and associated with detrimental metabolic 
consequences.
1-3
 Malnutrition is often a consequence of 
chronic disease and associated with higher mortality and 
morbidity, infection and longer hospital length of stay 
(LOS).
2,4,5
 These relationships have led to the current 
clinical approach of providing nutritional therapy during 
the acute phase of illness to reduce the consequences 
associated with malnutrition.
6
 Still, apart from critical 
care, there is a lack of clinical data from large 
randomized controlled trials (RCTs) in medical inpatients 
to support the early use of nutritional therapy.
6,7
 The 
Effect of early nutritional therapy on Frailty, Functional 
Outcomes and Recovery of malnourished medical 
inpatients Trial (EFFORT) was designed to close these 
gaps in the literature. 
Current evidence from randomized trials 
A systematic search and metanalysis published in 2016 
focusing on the clinical effects of nutritional 
interventions in medical inpatients compared to a control 
group found higher energy and protein intake in 
intervention group patients, as well as a reduction in the 
risk for unplanned hospital readmission and a 2-day 
reduction in length of hospital stay in the subgroup of 
patients with established malnutrition.
8,9
 However, no 
effects of nutritional therapy were found in regard to 
mortality, functional outcomes and other patient-relevant 
endpoints. Another recent Cochrane review investigating 
medical and surgical inpatients came to similar 
conclusions, demonstrating a lack of evidence on the 
effect of nutritional support on outcome.
10
 Both reviews 
also concluded that previous trials were highly 
heterogeneous in design, target populations and type of 
interventions, lacked power to demonstrate safety and in 
aggregate, thus produced inconclusive results. A very 
recent trial focusing on a specific protein-rich formula 
reported no difference in the primary combined adverse 
event outcome, but found lower mortality in patients 
receiving the nutritional intervention.
11
  
Are there potential harmful effects of nutritional 
interventions? 
Despite the absence of high-quality RCT data, the current 
clinical approach in general medical inpatients are to 
provide nutritional therapy to reach nutritional 
requirements. This approach has also recently been 
recommended by the European Society for Clinical 
Nutrition and Metabolism (ESPEN).
12
 Still, recent data 
from critical care have suggested potential harmful 
effects of aggressive early feeding possibly due to 
autophagy.
13-16
 Also, refeeding syndrome due to rapid 
start of nutrition in patients with severe malnutrition may 
cause negative clinical outcomes.
17
 Critical care data 
cannot unconditionally be generalized to medical 
inpatients. Importantly however, these conflicting 
observations re-emphasize that nutritional therapy is a 
medical intervention with associated risks and costs and 
call into question today`s nutritional approach to medical 
inpatients.
7,18
  
Rationale of the study and overall aim 
The current lack of strong and widely accepted guideline 
recommendations regarding type, energy amount and 
timing of nutritional therapy in medical inpatients is 
mainly explained by the paucity of high-level evidence 
showing such therapy’s effectiveness and cost benefits.12 
Hence, evaluation of effectiveness, safety and cost 
benefits within a large, well-controlled conclusive RCT is 
warranted to assess the effects of early nutritional therapy 
on patient outcomes in the medical inpatient setting. 
METHODS 
Study design 
EFFORT is an investigator-initiated, non-commercial, 
randomized controlled, pragmatic, superiority trial with 
an open intervention comparing the effects of an 
individualized nutritional intervention with a usual care 
control group. Figure 1 shows the principal patient flow 
diagram starting from screening, to inclusion and 
randomization, and assessment of patient outcomes. 
 
Figure 1: Trail flow. 
Setting and patient eligibility for inclusion and 
recruitment 
The multicenter trial includes eight secondary and tertiary 
care hospitals within Northern Switzerland, namely the 
University Clinical and Univerity hospital in Aarau and 
Bern, the Kantonsspital in Lucerne, Solothurn, St. Gallen, 
Münsterlingen and Baselland, and the Spital Lachen.  
Upon hospital admission, consecutive adult (age ≥18 
years) medical inpatients are screened for malnutrition 
risk by the nursing and /or physician staff, using the 
Nutritional Risk Screening (NRS), 2002 edition).
19,20
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Patients are eligible within 48 hours of admission if they 
fulfill all inclusion criteria below. 
Included are consecutive medical inpatients if they meet 
the following criteria. 
a) NRS ≥3 points  
b) expected length of hospital stay >4 days 
c) willingness to provide informed consent  
Excluded are patients who meet the following criteria. 
a) Initially admitted to critical care units (except 
intermediate care) or surgical patients. 
b) Unable to ingest oral nutrition and thus need for 
enteral or parenteral nutrition. 
c) Patients scheduled for total parenteral nutrition or 
tube feeding. 
d) Patients treated with nutritional therapy upon 
admission.  
e) In terminal condition (end of life situation).  
f) Hospitalized because of anorexia nervosa, acute 
pancreatitis, acute liver failure, cystic fibrosis or 
stem cell transplantation. 
g) Malnutrition after gastric bypass surgery. 
h) Any contraindication against nutritional therapy.   
i) Earlier inclusion into the trial. 
Data collected at study entry 
After trial inclusion, each patient receives a structured 
systematic medical and nutritional assessment by a study 
dietician including: 
 Socio-demographic and anthropometric data (e.g., 
age, weight and height for calculation of body-mass 
index [BMI]). 
 Baseline muscle strength (hand grip strength) and 
functional status using Barthel`s index.
21
 
 Medical diagnoses according to the ICD10-codes.  
During follow-up, all patients are daily re-assessed by a 
dietician to re-evaluate nutritional intake and whether 
nutritional targets are met. If patients in the intervention 
group do not reach the nutritional targets (<75%), their 
nutritional strategy is escalated according to the 
nutritional guidelines (see below).  
We systematically collect blood samples upon study 
inclusion and after 7 days for later batch measurement of 
nutritional markers and other biomarkers. If clinically 
indicated, there is pre-prandial measurement of blood 
glucose levels 4 times daily and anti-diabetic treatment in 
all patients as part of usual clinical practice.  
Randomization 
Eligible patients are randomized in a 1:1 fashion into the 
intervention group or the control group according to a 
pre-specified, computer-generated, web-based 
randomization scheme using the secuTrial© Software 
(managed and secured by the clinical trial unit of the 
University of Basel, Switzerland). The randomization is 
stratified for the trial site and initial NRS.  
Study endpoints 
All patients are daily assessed until hospital discharge 
and contacted after 30 days via telephone for a structured 
interview by blinded study nurses to assess primary and 
secondary endpoints. We will assess long-term outcomes 
by doing additional interviews after 6 month and possibly 
later.  
The primary composite endpoint consists of combined 
adverse outcomes within 30 days defined as, 
a) All-cause mortality 
b) Admission to the intensive care unit from the 
medical ward 
c) Unplanned hospital readmission after discharge 
d) Major complications (defined according to previous 
trials) as a new occurrence (i.e., being diagnosed 
after inclusion into the trial) of,
22
   
I. Nosocomial infection or abscess requiring 
antibiotic treatment  
II. Respiratory failure with need for invasive or 
non-invasive ventilation (continuous positive 
airway pressure, CPAP)  
III. Major cardiovascular event (stroke, 
intracranial bleeding, cardiac arrest, 
myocardial infarction with and without 
invasive procedure) or pulmonary embolism 
IV. Acute renal failure (defined by 2x increase of 
baseline creatinine or new requirement of 
dialysis do to volume overload or electrolyte 
disturbance)  
V. Gastro-intestinal failure (hemorrhage, 
intestinal perforation, pancreatitis [defined as 2 
out of 3 criteria: abdominal pain, 3-fold 
increase in lipase or pancreas-specific amylase, 
characteristic imaging findings]) 
e) Decline in functional status of 10% or more from 
admission to day 30 measured by the Barthel`s 
index.
23
 This index measures performance in 
activities of daily living and comprises two groups 
of items, one related to self-care (feeding, grooming, 
bathing, dressing, bowel and bladder care, and toilet 
use), the other related to mobility (ambulation, 
transfers, and stair climbing). We will use the 
German translatation which has a score ranging 
from 100 to 0 with lower scores indicating more 
severe disability.  
Secondary endpoints are defined as follows:  
a) Each single component of the primary endpoint at 
day 30. 
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b) Each single component of the primary endpoint and 
the combined endpoint at short term, i.e., at day 7 or 
hospital discharge whatever comes first. 
c) Short-term nutritional and functional outcomes from 
inclusion to day 7 or hospital discharge (whatever 
comes first) including nutritional intake, 
improvement in muscle strength measured with 
handgrip strength
24
, lean body mass, changes in 
undernutrition markers (pre-albumin, retinol-
binding protein, body weight, BMI. 
d) Hospital outcomes measured at hospital discharge 
defined as total LOS, discharge home vs. post-acute 
care facility, new decubital ulcer. 
e) Improvement in quality of life measured on 
admission and at 30-day using the EuroQol Group 
5-Dimension Self-Report Questionnaire and 
selected items from the Functional Assessment 
Anorexia-Cancer Therapy [FAACT] 
questionnaire).
25,26
 
f) Single component of the primary endpoint and the 
combined endpoint at long term, i.e., at day 180 or 
later. 
Safety endpoints including side effects from nutritional 
therapy are daily assessed until hospital discharge and are 
defined as:  
a) Adverse gastrointestinal effects (e.g. obstipation, 
diarrhea, nausea, vomiting, abdominal pain). 
b) Complications due to tube feeding or central venous 
catheter for parenteral nutrition. 
c) Refeeding syndrome defined according to a recent 
consensus definition.
17,27
 
d) Liver or gallbladder dysfunction. 
e) Hyperglycemia (defined as persistent levels >10 
mmol/l in patients without diabetes or well 
controlled diabetes).  
Nutritional treatment of intervention group and control 
group patients 
Prior to this study, there was no international guideline 
for the nutritional treatment of polymorbid medical 
inpatients as most international societies focused on 
disease- or organ-specific guidelines. For this purpose, 
we thus developed nutritional guidelines in cooperation 
with the European Society for Clinical Nutrition and 
Metabolism (ESPEN).
12
 We also developed a pragmatic 
nutritional algorithm by consensus in accordance to 
current guidelines which illustrates the nutritional 
approach to the medical inpatient (Figure 2).
12,28-41
  
In brief, as a first step, all medical patients entering the 
hospital are assessed with a validated screening tool, i.e. 
the NRS, to identify patients with nutritional deficits 
potentially eligible for the trial.
42
 Patients admitted to 
acute care hospitals are screened within 48 hours. In 
patients with nutritional risk defined as a NRS of ≥3 
points and willingness to start nutritional therapy, 
nutritional goals are defined. These include energy and 
protein goals, micronutrient goals and other disease-
specific targets. Energy requirements of hospitalized 
patients differ depending physical activity, stress factors 
and resting energy requirements. These requirements can 
be predicted using the Harris-Benedict equation, when 
indirect calorimetry is not available. For under- and 
overweight patients, the formula has to be adjusted for 
body weight to improve its accuracy.
43
 We also 
recommend that protein intake should be high as a 
compensation for higher protein breakdown and to avoid 
loss of total body protein mass and malnutrition.
44
 We 
recommend a protein intake of 1.2-1.5 g kg
-1
·d
-1
, except 
for patients with acute renal failure who are not 
dependant on renal replacement therapy where targets are 
at 0.8 g kg
-1
·d
-1
. Also, micronutrient and vitamins 
deficiencies are common among these patients. Providing 
patients with supplementation (such as multivitamin and 
multimineral supplements) is thus recommended. 
 
Figure 2: Nutritional guidelines used for intervention 
group patients. 
Once goals are set, a nutritional plan to achieve these 
goals is important. It is recommended to first rely on oral 
nutrition including food adjustment according to patient 
preferences, food fortification of meals and providing 
patients with between-meal snacks. Also, oral nutritional 
supplements should be used to meet nutritional 
requirements.
45,46
 Although oral feeding constitutes the 
most physiological route of feeding, it is not always 
sufficient to treat malnutrition, especially in cases of 
acute illness and low appetite. Enteral feeding should be 
implemented if at least 75% of energy and protein targets 
cannot be reached within 5 days of oral feeding. Intakes 
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should be reassessed every 24-48 h. Enteral feeding can 
be provided by nasogastric tube or percutaneous 
endoscopic gastrostomy (PEG) depending on how long it 
is predicted. A multivitamin and multi-mineral 
supplement is not needed if enteral feeding provides at 
least 1500 kcal·d
-1
. Last, if the enteral route fails to 
achieve the goal of providing at least 75% of energy and 
protein targets, start of parenteral nutrition with a 
minimal oral or enteral feeding is recommended.   
In control patients, we use standard care, i.e. food 
provided by the hospital kitchen according to the 
patient`s ability and desire to eat (“appetite-guided”). 
However, nutritional therapy may be initiated in control 
patients at any time, if new swallowing disorders develop 
or if patients need to be prepared for surgical 
interventions. Similarly, nutritional therapy may be 
discontinued in intervention group patients becoming 
terminal or developing a condition where oral nutritional 
therapy is contraindicated (e.g., intestinal perforation). 
Thus, in both groups the nutritional therapy protocol may 
be overruled after discussion with the principle 
investigator (PI) and the involved study coordinators. 
Ethical considerations 
The study was approved by the institutional ethics 
committees (IEC) of the participating hospitals and 
conducted in compliance with the protocol approved by 
the IEC, and according to international conference of 
harmonisation 
(ICH)-Good Clinical Practice standards. All enrolled 
patients are asked to give written informed consent. In 
patients in which “informed consent” is not feasible due 
to dementia or their acute medical condition, patients’ 
next to kin can sign an assent form to state the 
presumptive will of the patient. In case the next of kin is 
not readily available, a treating physician – who must not 
be involved in the study – must certify that there are no 
objections for study inclusion, from his point of view. 
Only after these informed consent procedures the patient 
can be included in the study.  
Importantly, despite strong associations between 
malnutrition and adverse clinical outcome, we believe 
that is ethically acceptable that the control group receives 
no additional nutritional treatment because there is 
uncertainty about the effectiveness and safety of 
nutritional therapy in this patient population. This 
important subject has been discussed among national 
experts in the field (i.e., trial collaborators) who all 
agreed to this practice. This is also in accordance with a 
previous Swiss consensus ethical statement pointing out 
that “intake of standard food and fluids is a basic right of 
any patients”, yet any sort of nutritional therapy must be 
viewed as a therapeutic measure and must therefore fulfill 
all criteria for such including proof of clinical 
effectiveness, safety and cost-effectiveness.
47
 For our 
patient population, such proofs are still missing and are 
thus the main aim of this trial. 
Patient and public involvement statement 
Patients were not involved in the design of the trial. We 
did involve patient in the recruitment process and patients 
also provided answers to questionnaires during the intitial 
screening and inclusion period, as well as during follow 
up. Patients in the intervention group also followed the 
instructions regarding nutritional therapy as addressed by 
a study dietician. 
Statistical approach 
Detailed methodology for summaries and statistical 
analyses of the data collected in this study will be 
documented in a statistical analysis plan. First, a consort 
diagram will be reported as recommended (Figure 3). The 
primary analysis population is the full analysis set, which 
includes all randomized patients following an intention-to 
treat (ITT) principle. Every effort is made to minimize 
the number of patients lost to follow-up.  
 
Figure 3: Consort patient flow diagram. 
Primary and secondary endpoints will be compared 
between trial arms in the overall ITT population and 
within predefined subgroups as discussed below. All 
outcomes will be analyzed in an unadjusted manner as 
well as jointly adjusted for the main risk factors 
(Barthel`s index at baseline, study center and initial NRS 
categories). For our primary analysis, we will compare 
the two arms with a chi-square test and we will also 
estimate effect size with a logistic regression models 
reporting unadjusted and adjusted odds ratios (OR) and 
corresponding 95% confidence intervals (CIs).  
We will do different predefined subgroup analyses by 
including interaction terms in the regression model to test 
for effect modification by important baseline factors. 
Specifically, we will look at patients age (<60, 60-75, 
>75 years), gender, risk for undernutrition stratified 
according to initial NRS score (3, 4, >4 points), BMI 
(<20, 20-25, >25-30, >30), main medical diagnosis 
(systemic infection, heart failure, acute renal failure, 
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gastro-intestinal disease, tumor), comorbidities (diabetes, 
chronic renal failure), LOS (<8 days, ≥8 days).  
Sample size considerations 
This study is designed to show superiority of intensified 
nutritional therapy compared to “appetite-guided” 
standard care regarding the composite primary endpoint. 
Our primary hypothesis is that early nutritional therapy 
will reduce adverse clinical outcome and mortality within 
a follow up period of 30 days after the index 
hospitalization. From preliminary observational data,
48
 
we estimate that 40% of the target patient population 
(NRS ≥3 points and LOS ≥5 days) will reach the primary 
endpoint within 30 days (10% mortality, 5% ICU 
admission from the hospital ward, 15% complications, 
10% functional decline with 10% of patients reaching 
more than 1 endpoint). We hypothesize that our 
nutritional intervention will decrease this risk by an 
absolute number of 6% (relative decrease of 15%), i.e., 
from 40% to 34%. For a comparison of two independent 
binomial proportions using Pearson's Chi-square statistic 
with a Chi-square approximation with a two-sided 
significance level of 0.05, a sample size of 1016 per 
group (total number 2032) achieves a power of at least 
80% when the proportions are 0.40 and 0.34. The 
inclusion of 1359 patients per group would increase the 
power to 90%. Table 1 shows sample sizes for different 
assumptions regarding effectiveness of our intervention 
and power. In practice, due to funding restrictions, we 
recruit patients until early 2018 and all patients recruited 
in that period will be randomized unless the sample size 
is below 2032 patients, which would lead to an extension 
of the recruitment period. If recruitment of >3000 
patients is reached before that, we will stop the trial early. 
Table 1: Sample size considerations in regard to the primary endpoint. 
Frequency of 1° EP 
control group 
Frequency of 1° EP 
experimental group 
Difference control/intervention 
groups (%) 
Power 
Patients per 
group 
0.4 0.36 -10 0.80 2311 
0.4 0.36 -10 0.85 2643 
0.4 0.36 -10 0.90 3093 
0.4 0.34 -15 0.80 1016 
0.4 0.34 -15 0.85 1162 
0.4 0.34 -15 0.90 1359 
0.4 0.32 -20 0.80 564 
0.4 0.32 -20 0.85 645 
0.4 0.32 -20 0.90 755 
 
DISCUSSION 
Nutrition is essential for survival and physical condition 
in health and disease. Despite its centrality to hospital 
practice, nutritional therapy has not been well-studied and 
high-quality evidence of efficacy, safety and cost-
effectiveness in acutely-ill medical inpatients outside 
critical care is lacking.
8
 These gaps and ambiguities in the 
literature as well as recent evidence from critically ill 
patients suggesting potential harmful effects of nutritional 
therapy are of concern.
4,49
 EFFORT aims to establish an 
evidence-based standard for nutritional therapy in 
medical inpatients. Using a physio-pathological 
mechanistic approach, EFFORT will also increase basic 
understanding on how nutrition affects acute disease and 
vice versa. Further, by incorporating pharmaco-economic 
research, EFFORT will elucidate the indications in which 
nutritional therapy - currently associated with substantial 
healthcare costs because of its widespread application - is 
cost-effective. Thus, EFFORT will facilitate a more 
efficient healthcare resource distribution.  
EFFORT is the largest-yet nutritional RCT outside 
critical care to provide definitive evidence about expected 
benefits and harms of this intervention in the medical 
inpatient population. Additionally, EFFORT aims to 
study physio-pathological mechanisms associated with 
the interplay of nutrition and disease, and to measure the 
therapeutic value of an intensified nutrition strategy. 
Towards this aim, we have planned several secondary 
projects focusing on mechanistic research questions. 
Comparative effectiveness research aims at improving 
quality, effectiveness, and efficiency of health care and 
supporting patients and healthcare professionals decision 
making.
50
 To achieve these goals, research must address 
the patient population that consumes the most health care 
resources, specifically polymorbid, frail, elderly patients 
with complex combinations of medical diagnoses. 
Although this patient population accounts for the 
majority of costs, it is also the least studied population.
51
 
To correct this disparity, clinical trials should include 
large, representative populations, to enable examination 
of treatment effects within key subpopulations, and to 
allow robust head-to-head comparison of interventions.
50
 
In the case of nutritional therapy, most previous trials 
looked at specific patient populations only, excluding 
frail general medical inpatients. EFFORT will help to 
close this gap. EFFORT focuses on a major issue in 
hospital care, namely, whether, how and why early 
nutritional therapy affects outcomes of elderly, frail 
medical inpatients. Evidence generated by this project 
will therefore easily be transferable to clinical practice 
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and thus can be expected to directly exert a major impact 
on current patient management. 
We are aware of several potential limitations to the 
successful completion and interpretation of this trial. 
First, inclusion of 2000-3000 patients over the funding 
time frame is ambitious. However, based on a well-
established multicenter research network, our large 
experience from previous multicenter RCTs, and the high 
prevalence of hospitalized patients potentially eligible for 
this trial, we are convinced that the trial is feasible. Pilot 
data from a current observational cohort study have 
shown that the University Department of Medicine at the 
Kantonsspital Aarau by itself has about 8,000 medical 
hospitalizations per year, among which about 1,000 
patients per year have an NRS≥3 points, a LOS >4 days 
and would thus be enrollment candidates.
48
 As a second 
limitation, there is no blinding of patients or caregivers 
regarding the randomization arm, which might reveal 
bias. However, outcome assessment at day 30, including 
for the primary endpoint and most secondary endpoints 
will be blinded. Due to the variety of nutritional options 
to reach the nutritional goals, we agreed that a placebo 
control group would be neither feasible, nor ethical.  
Third, there is potential for control group “performance 
bias”, i.e., if the caregiver staff feels obliged to motivate 
patients in the control group to increase their food 
consumption. A complex intervention such as nutritional 
therapy must be implemented at different levels and by 
the full care team in the hospital. While dieticians 
recommend individualized strategies for patients, the 
physician staff need to support the strategy and motivate 
the patient, and, most importantly, the nursing team is 
key in everyday application of the strategy, i.e., actively 
encouraging, and if needed, feeding the patient. It will 
thus be important to continuously educate the caregiver 
staff about the intention of this trial, and the potential 
risks of nutritional therapy which have not yet been well-
studied in the population in question. Fourth, it is 
expected that not all patients in the intervention group 
reach their energy and protein goals and some may refuse 
enteral and parenteral nutrition. However, as a pragmatic 
trial, we are most interested in the effects of nutritional 
therapy in “real life” using a state-of-the-art algorithm. 
Still, we will document actual nutritional intake and later 
study the effect of compliance on our intervention. 
In conclusion, this pragmatic comparative effectiveness 
research project was planned to improve the quality, 
effectiveness, safety and efficiency of nutritional 
“therapy” and basic understanding of the relationship 
between nutrition and illness. Data acquired through 
EFFORT will thus help healthcare professionals and 
payers worldwide to make better-informed decisions 
regarding care of frail, elderly and polymorbid 
individuals with acute illness, who represent a large and 
growing patient population worldwide, and one that 
accounts for a major share of medical resource 
consumption.  
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